Trial Outcomes & Findings for Prospective Evaluation of 14F Thal Tube vs 28 French Chest Tube for Hemothorax and Use of Maximum Barrier Precautions (NCT NCT03167723)
NCT ID: NCT03167723
Last Updated: 2023-03-29
Results Overview
Number of Participants with Retained hemothorax requiring an additional intervention, either video-assisted thoracoscopic surgery (VATS) or additional thoracostomy tube placement.
COMPLETED
NA
193 participants
90 days
2023-03-29
Participant Flow
Excluded (n=84) Hemodynamic instability (n=36) Chest tube placed at outside facility (n=12) Multiple chest tube placement (n=10) Declined to participate (n=1) Not meet inclusion criteria (n=6) Other reasons (n=19)
Participant milestones
| Measure |
28 French Chest Tube for Hemothorax
28 French straight chest tube placed for non-emergent drainage of hemothorax or hemopneumothorax
Chest tube placement: Placing tube thoracostomy for hemothorax or hemopneumothorax utilizing maximal barrier precautions.
|
14 French Chest Tube for Hemothorax
14 French thal chest tube placed for non-emergent drainage of hemothorax or hemopneumothorax
Chest tube placement: Placing tube thoracostomy for hemothorax or hemopneumothorax utilizing maximal barrier precautions.
|
|---|---|---|
|
Overall Study
STARTED
|
55
|
54
|
|
Overall Study
COMPLETED
|
51
|
48
|
|
Overall Study
NOT COMPLETED
|
4
|
6
|
Reasons for withdrawal
| Measure |
28 French Chest Tube for Hemothorax
28 French straight chest tube placed for non-emergent drainage of hemothorax or hemopneumothorax
Chest tube placement: Placing tube thoracostomy for hemothorax or hemopneumothorax utilizing maximal barrier precautions.
|
14 French Chest Tube for Hemothorax
14 French thal chest tube placed for non-emergent drainage of hemothorax or hemopneumothorax
Chest tube placement: Placing tube thoracostomy for hemothorax or hemopneumothorax utilizing maximal barrier precautions.
|
|---|---|---|
|
Overall Study
Protocol Violation
|
4
|
6
|
Baseline Characteristics
Race and Ethnicity were not collected from any participant.
Baseline characteristics by cohort
| Measure |
28 French Chest Tube for Hemothorax
n=55 Participants
28 French straight chest tube placed for non-emergent drainage of hemothorax or hemopneumothorax
Chest tube placement: Placing tube thoracostomy for hemothorax or hemopneumothorax utilizing maximal barrier precautions.
|
14 French Chest Tube for Hemothorax
n=54 Participants
14 French thal chest tube placed for non-emergent drainage of hemothorax or hemopneumothorax
Chest tube placement: Placing tube thoracostomy for hemothorax or hemopneumothorax utilizing maximal barrier precautions.
|
Total
n=109 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
49.9 years
n=55 Participants
|
46.5 years
n=54 Participants
|
49 years
n=109 Participants
|
|
Sex: Female, Male
Female
|
17 Participants
n=55 Participants
|
15 Participants
n=54 Participants
|
32 Participants
n=109 Participants
|
|
Sex: Female, Male
Male
|
38 Participants
n=55 Participants
|
39 Participants
n=54 Participants
|
77 Participants
n=109 Participants
|
|
Race and Ethnicity Not Collected
|
—
|
—
|
0 Participants
Race and Ethnicity were not collected from any participant.
|
|
Injury Severity Score - score that ranges from 3 (least) to 75 (most) injured
|
17 units on a scale
n=55 Participants
|
18 units on a scale
n=54 Participants
|
17 units on a scale
n=109 Participants
|
PRIMARY outcome
Timeframe: 90 daysNumber of Participants with Retained hemothorax requiring an additional intervention, either video-assisted thoracoscopic surgery (VATS) or additional thoracostomy tube placement.
Outcome measures
| Measure |
28 French Chest Tube for Hemothorax
n=51 Participants
28 French straight chest tube placed for non-emergent drainage of hemothorax or hemopneumothorax
Chest tube placement: Placing tube thoracostomy for hemothorax or hemopneumothorax utilizing maximal barrier precautions.
|
14 French Chest Tube for Hemothorax
n=48 Participants
14 French thal chest tube placed for non-emergent drainage of hemothorax or hemopneumothorax
Chest tube placement: Placing tube thoracostomy for hemothorax or hemopneumothorax utilizing maximal barrier precautions.
|
|---|---|---|
|
Number of Participants With Retained Hemothorax Following Initial Chest Tube Placement Requiring Intervention
|
51 Number of Participants
|
48 Number of Participants
|
SECONDARY outcome
Timeframe: 90 daysNumber of days with chest tube placement
Outcome measures
| Measure |
28 French Chest Tube for Hemothorax
n=51 Participants
28 French straight chest tube placed for non-emergent drainage of hemothorax or hemopneumothorax
Chest tube placement: Placing tube thoracostomy for hemothorax or hemopneumothorax utilizing maximal barrier precautions.
|
14 French Chest Tube for Hemothorax
n=48 Participants
14 French thal chest tube placed for non-emergent drainage of hemothorax or hemopneumothorax
Chest tube placement: Placing tube thoracostomy for hemothorax or hemopneumothorax utilizing maximal barrier precautions.
|
|---|---|---|
|
Duration of Chest Tube Placement.
|
3.9 days
Interval 2.6 to 5.3
|
3.9 days
Interval 2.8 to 5.8
|
SECONDARY outcome
Timeframe: 90 daysNumber of weeks spent in hospital
Outcome measures
| Measure |
28 French Chest Tube for Hemothorax
n=51 Participants
28 French straight chest tube placed for non-emergent drainage of hemothorax or hemopneumothorax
Chest tube placement: Placing tube thoracostomy for hemothorax or hemopneumothorax utilizing maximal barrier precautions.
|
14 French Chest Tube for Hemothorax
n=48 Participants
14 French thal chest tube placed for non-emergent drainage of hemothorax or hemopneumothorax
Chest tube placement: Placing tube thoracostomy for hemothorax or hemopneumothorax utilizing maximal barrier precautions.
|
|---|---|---|
|
Number of Participants Stratified by Length of Hospitalization Stay
1 Week
|
20 Number of Participants
|
15 Number of Participants
|
|
Number of Participants Stratified by Length of Hospitalization Stay
2 Weeks
|
19 Number of Participants
|
15 Number of Participants
|
|
Number of Participants Stratified by Length of Hospitalization Stay
3 Weeks
|
7 Number of Participants
|
6 Number of Participants
|
|
Number of Participants Stratified by Length of Hospitalization Stay
> or = 4 Weeks
|
5 Number of Participants
|
12 Number of Participants
|
SECONDARY outcome
Timeframe: 90 daysAssessed with 0-10 numeric pain rating scale - the higher the number, the more severe the pain
Outcome measures
| Measure |
28 French Chest Tube for Hemothorax
n=51 Participants
28 French straight chest tube placed for non-emergent drainage of hemothorax or hemopneumothorax
Chest tube placement: Placing tube thoracostomy for hemothorax or hemopneumothorax utilizing maximal barrier precautions.
|
14 French Chest Tube for Hemothorax
n=48 Participants
14 French thal chest tube placed for non-emergent drainage of hemothorax or hemopneumothorax
Chest tube placement: Placing tube thoracostomy for hemothorax or hemopneumothorax utilizing maximal barrier precautions.
|
|---|---|---|
|
Change in Subjective Pain Scores From Baseline at 90 Days
|
0 units on a scale
Interval -1.0 to 2.0
|
0 units on a scale
Interval -2.0 to 2.0
|
SECONDARY outcome
Timeframe: 90 daysdetermined by vital signs: temperature, heart rate, blood pressure, oxygen saturation (Systolic Blood Pressure \<90mm Hg)
Outcome measures
| Measure |
28 French Chest Tube for Hemothorax
n=51 Participants
28 French straight chest tube placed for non-emergent drainage of hemothorax or hemopneumothorax
Chest tube placement: Placing tube thoracostomy for hemothorax or hemopneumothorax utilizing maximal barrier precautions.
|
14 French Chest Tube for Hemothorax
n=48 Participants
14 French thal chest tube placed for non-emergent drainage of hemothorax or hemopneumothorax
Chest tube placement: Placing tube thoracostomy for hemothorax or hemopneumothorax utilizing maximal barrier precautions.
|
|---|---|---|
|
Hemodynamic Stability Post-insertion
|
2 Number of Participants
|
1 Number of Participants
|
SECONDARY outcome
Timeframe: 5 MinutesMilliliters of chest tube drainage at 5 minutes
Outcome measures
| Measure |
28 French Chest Tube for Hemothorax
n=51 Participants
28 French straight chest tube placed for non-emergent drainage of hemothorax or hemopneumothorax
Chest tube placement: Placing tube thoracostomy for hemothorax or hemopneumothorax utilizing maximal barrier precautions.
|
14 French Chest Tube for Hemothorax
n=48 Participants
14 French thal chest tube placed for non-emergent drainage of hemothorax or hemopneumothorax
Chest tube placement: Placing tube thoracostomy for hemothorax or hemopneumothorax utilizing maximal barrier precautions.
|
|---|---|---|
|
Initial Drainage From Chest Tube at 5 Minutes
|
150 mL
Interval 60.0 to 500.0
|
100 mL
Interval 3.5 to 350.0
|
SECONDARY outcome
Timeframe: 90 daysNumber of Tube specific complications: Air leak, tube malposition, \& tube migration
Outcome measures
| Measure |
28 French Chest Tube for Hemothorax
n=51 Participants
28 French straight chest tube placed for non-emergent drainage of hemothorax or hemopneumothorax
Chest tube placement: Placing tube thoracostomy for hemothorax or hemopneumothorax utilizing maximal barrier precautions.
|
14 French Chest Tube for Hemothorax
n=48 Participants
14 French thal chest tube placed for non-emergent drainage of hemothorax or hemopneumothorax
Chest tube placement: Placing tube thoracostomy for hemothorax or hemopneumothorax utilizing maximal barrier precautions.
|
|---|---|---|
|
Tube Specific Complications: Air Leak, Tube Malposition, & Tube Migration
|
7 Ocurrences
|
5 Ocurrences
|
SECONDARY outcome
Timeframe: 90 daysNumber of days until radiographic resolution of pneumothorax/hemothorax/hemopneumothorax
Outcome measures
| Measure |
28 French Chest Tube for Hemothorax
n=51 Participants
28 French straight chest tube placed for non-emergent drainage of hemothorax or hemopneumothorax
Chest tube placement: Placing tube thoracostomy for hemothorax or hemopneumothorax utilizing maximal barrier precautions.
|
14 French Chest Tube for Hemothorax
n=48 Participants
14 French thal chest tube placed for non-emergent drainage of hemothorax or hemopneumothorax
Chest tube placement: Placing tube thoracostomy for hemothorax or hemopneumothorax utilizing maximal barrier precautions.
|
|---|---|---|
|
Time to Radiographic Resolution of Pneumothorax/Hemothorax/Hemopneumothorax
|
0.5 days
Interval 0.1 to 2.7
|
1 days
Interval 0.1 to 2.7
|
SECONDARY outcome
Timeframe: 90 daysNumber of Participants with Recurrent pneumothorax/hemothorax/hemopneumothorax after tube removal
Outcome measures
| Measure |
28 French Chest Tube for Hemothorax
n=51 Participants
28 French straight chest tube placed for non-emergent drainage of hemothorax or hemopneumothorax
Chest tube placement: Placing tube thoracostomy for hemothorax or hemopneumothorax utilizing maximal barrier precautions.
|
14 French Chest Tube for Hemothorax
n=48 Participants
14 French thal chest tube placed for non-emergent drainage of hemothorax or hemopneumothorax
Chest tube placement: Placing tube thoracostomy for hemothorax or hemopneumothorax utilizing maximal barrier precautions.
|
|---|---|---|
|
Recurrent Pneumothorax/Hemothorax/Hemopneumothorax After Tube Removal
|
5 participants
|
1 participants
|
SECONDARY outcome
Timeframe: 90 daysNumber of Participants readmitted for chest tube related complications
Outcome measures
| Measure |
28 French Chest Tube for Hemothorax
n=51 Participants
28 French straight chest tube placed for non-emergent drainage of hemothorax or hemopneumothorax
Chest tube placement: Placing tube thoracostomy for hemothorax or hemopneumothorax utilizing maximal barrier precautions.
|
14 French Chest Tube for Hemothorax
n=48 Participants
14 French thal chest tube placed for non-emergent drainage of hemothorax or hemopneumothorax
Chest tube placement: Placing tube thoracostomy for hemothorax or hemopneumothorax utilizing maximal barrier precautions.
|
|---|---|---|
|
Readmission for Chest Tube Related Complications
|
9 participants
|
4 participants
|
Adverse Events
28 French Chest Tube for Hemothorax
14 French Chest Tube for Hemothorax
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place